期刊
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
卷 32, 期 1, 页码 94-101出版社
WILEY
DOI: 10.1002/gps.4450
关键词
antidepressant; Alzheimer's disease; incidence
资金
- GlaxoSmithKline
- Janssen-Cilag
- Bristol-Myers Squibb
- Eli Lilly
- Pfizer
- Lundbeck
- AstraZeneca
- Novartis
- Stanley Foundation
ObjectivesThe study aimed to investigate the incidence of antidepressant use in persons with and without Alzheimer's disease (AD) from 9years before to 4years after AD diagnosis and to examine the incidence of different antidepressant groups. MethodsWe used register-based data from the Medication use and Alzheimer's disease cohort including all Finnish persons diagnosed with AD in 2005-2011 with their age-matched and gender-matched comparison persons without AD. In this study, 62,104 persons with AD and 62,104 comparison persons were included. Data on dispensed antidepressants during 1995-2012 were collected from the Prescription Register. A 1-year washout period was utilized to measure the rate of new antidepressant users every 6-month period starting from 9years before and until 4years after the AD diagnoses. The incidence rate between persons with and without AD was compared with Poisson regression. ResultsThe incidence of antidepressant use in persons with AD was higher during the whole study period compared with that in persons without AD. The incidence rate was highest at 6months after AD diagnosis (incidence rate ratio=5.22, 95% confidence interval 4.77-5.72). Selective serotonin reuptake inhibitors were the most frequently initiated group (61.3% of initiations in persons with AD). ConclusionsThe incidence of antidepressant use was higher in persons with AD than in comparison persons, and it was not explained by history of hospital-treated psychiatric disorders. Widespread use of antidepressants in persons with AD is concerning as their efficacy is controversial and their use is associated with adverse events. Copyright (c) 2016 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据